Zinbryta

Zinbryta
Generic Name: daclizumab (dah KLIH zyoo mab)
Brand Names: Zinbryta
Company: Biogen
FDA Approved: May 2016

Zinbrtya is specifically indicated for the treatment of adult patients with relapsing forms of multiple sclerosis. Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Zinbryta dosing information
Usual Adult Dose for Multiple Sclerosis:

17 years and older:
150 mcg subcutaneously once a month

Comments:
-Sites for injection are the thigh, abdomen, and back of the upper arm.
-If a dose is missed within 2 weeks of the scheduled dose, it should be given immediately and the original monthly dosing schedule should be resumed.
-If a dose is missed and it is more than 2 weeks from the scheduled dose, the missed dose should be skipped and the original monthly dosing schedule should be resumed.
-Only one dose should be administered at one time.

Use: For the treatment of adult patients with relapsing forms of multiple sclerosis (MS) who have had an inadequate response to 2 or more drugs